The share price of ) dropped by 16% on Thursday. The company traded down to GBX 28,50 ($0.36) before trading at GBX 31,50 ($0.39). Around 150,049 share traded hands at midday, an increase by 547% compared to the average daily trading volume of 23,194 Shares. The stock closed earlier at GBX37.50 ($0.47).
Fusion Antibodies Trade Down 16.0%
The market capitalization is PS8.19m, the P/E ratio is -525.00, and beta is 0.21. The company's fifty-day moving average is GBX 36.03, and its 200-day moving average is GBX42.55. The company's quick ratio is 2.36, its current ratio is 2.84 and its debt-to equity ratio is 12.95.
Fusion Antibodies plc is a contract research organisation that specializes in research, development and manufacturing of recombinant antibodies and proteins, primarily to treat cancer and infectious disease in the United Kingdom and other parts of Europe. It also operates in North America and internationally. The company provides monoclonal antibodies discovery and development services, as well as antibody sequencing, engineering, humanization of antibodies, rational affinity maturation, recombinant proteins expression, stable cell line and cGMP scaling up.
MarketBeat.com offers a FREE daily email newsletter